These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33788282)

  • 1. Zebrafish as a tractable model of human cardiovascular disease.
    Bowley G; Kugler E; Wilkinson R; Lawrie A; van Eeden F; Chico TJA; Evans PC; Noël ES; Serbanovic-Canic J
    Br J Pharmacol; 2022 Mar; 179(5):900-917. PubMed ID: 33788282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical rodent models of cardiac fibrosis.
    Wang Y; Wang M; Samuel CS; Widdop RE
    Br J Pharmacol; 2022 Mar; 179(5):882-899. PubMed ID: 33973236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-arrhythmic investigations in large animal models of atrial fibrillation.
    Saljic A; Jespersen T; Buhl R
    Br J Pharmacol; 2022 Mar; 179(5):838-858. PubMed ID: 33624840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on small molecules in cardiovascular diseases.
    Wang X; Huang Y; Ji Y
    Br J Pharmacol; 2018 Apr; 175(8):1111-1113. PubMed ID: 29574891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal models of diabetes-associated vascular diseases: an update on available models and experimental analysis.
    Choi JSY; de Haan JB; Sharma A
    Br J Pharmacol; 2022 Mar; 179(5):748-769. PubMed ID: 34131901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical models of myocardial infarction: from mechanism to translation.
    Martin TP; MacDonald EA; Elbassioni AAM; O'Toole D; Zaeri AAI; Nicklin SA; Gray GA; Loughrey CM
    Br J Pharmacol; 2022 Mar; 179(5):770-791. PubMed ID: 34131903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rodent models of hypertension.
    Jama HA; Muralitharan RR; Xu C; O'Donnell JA; Bertagnolli M; Broughton BRS; Head GA; Marques FZ
    Br J Pharmacol; 2022 Mar; 179(5):918-937. PubMed ID: 34363610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The canine chronic atrioventricular block model in cardiovascular preclinical drug research.
    Loen V; Vos MA; van der Heyden MAG
    Br J Pharmacol; 2022 Mar; 179(5):859-881. PubMed ID: 33684961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic rabbit models for cardiac disease research.
    Hornyik T; Rieder M; Castiglione A; Major P; Baczko I; Brunner M; Koren G; Odening KE
    Br J Pharmacol; 2022 Mar; 179(5):938-957. PubMed ID: 33822374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the mineralocorticoid receptor in immune cells in cardiovascular disease.
    van der Heijden CDCC; Bode M; Riksen NP; Wenzel UO
    Br J Pharmacol; 2022 Jul; 179(13):3135-3151. PubMed ID: 34935128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.
    Helmstädter J; Keppeler K; Küster L; Münzel T; Daiber A; Steven S
    Br J Pharmacol; 2022 Feb; 179(4):659-676. PubMed ID: 33764504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse models for abdominal aortic aneurysm.
    Golledge J; Krishna SM; Wang Y
    Br J Pharmacol; 2022 Mar; 179(5):792-810. PubMed ID: 32914434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tandem stenosis mouse model: Towards understanding, imaging, and preventing atherosclerotic plaque instability and rupture.
    Noonan J; Bobik A; Peter K
    Br J Pharmacol; 2022 Mar; 179(5):979-997. PubMed ID: 33368184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal models of pulmonary hypertension: Getting to the heart of the problem.
    Dignam JP; Scott TE; Kemp-Harper BK; Hobbs AJ
    Br J Pharmacol; 2022 Mar; 179(5):811-837. PubMed ID: 33724447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboinflammation in coronavirus disease 2019: The clot thickens.
    Iffah R; Gavins FNE
    Br J Pharmacol; 2022 May; 179(10):2100-2107. PubMed ID: 34128218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of mitochondrial dynamics in cardiovascular diseases.
    Forte M; Schirone L; Ameri P; Basso C; Catalucci D; Modica J; Chimenti C; Crotti L; Frati G; Rubattu S; Schiattarella GG; Torella D; Perrino C; Indolfi C; Sciarretta S;
    Br J Pharmacol; 2021 May; 178(10):2060-2076. PubMed ID: 32294237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting vascular (endothelial) dysfunction.
    Daiber A; Steven S; Weber A; Shuvaev VV; Muzykantov VR; Laher I; Li H; Lamas S; Münzel T
    Br J Pharmacol; 2017 Jun; 174(12):1591-1619. PubMed ID: 27187006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor in cardiovascular diseases-Clinical trials and mechanistic insights.
    Bauersachs J; López-Andrés N
    Br J Pharmacol; 2022 Jul; 179(13):3119-3134. PubMed ID: 34643952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards a druggable epitranscriptome: Compounds that target RNA modifications in cancer.
    Berdasco M; Esteller M
    Br J Pharmacol; 2022 Jun; 179(12):2868-2889. PubMed ID: 34185879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting inflammation to reduce cardiovascular disease risk.
    Maffia P; Cirino G
    Br J Pharmacol; 2017 Nov; 174(22):3895-3897. PubMed ID: 29080212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.